MedTrace Logo

Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)

NCT04055038 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2019-08-13

No results posted yet for this study

Summary

This is a phase II/III randomized controlled trial to evaluate efficacy of platinum-based chemotherapy vs conventionally prescribed non-platinum monochemotherapy in patients with platinum-resistant ovarian cancer

Conditions

  • Ovarian Cancer
  • Ovarian Neoplasms
  • Serous Adenocarcinoma
  • BRCA1 Mutation
  • BRCA2 Mutation
  • Chemotherapy

Interventions

DRUG

Platinum-Based Drug

Reintroduction of platinum-based chemotherapy

DRUG

Conventional chemotherapy

Conventional chemotherapy

Sponsors & Collaborators

  • Blokhin's Russian Cancer Research Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2021-09-01
Completion
2022-01-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04055038 on ClinicalTrials.gov